More than 250 miles above the Earths surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.
The National Stem Cell Foundation (NSCF) is funding the study, which is the result of a bi-coastal collaboration between the New York Stem Cell Foundation (NYSCF) Research Institute and Aspen Neuroscience, a San Diego startup developing personalized cell therapies for Parkinsons disease.
Collaborating with the New York Stem Cell Foundation (NYSCF) Research Institute on the other side of the country, the two teams have been working together for more than two years, exchanging and sharing technology to develop patient-derived, induced pluripotent stem cell (iPSC) organoid models.
The 3D human organoid models were launched to the International Space Station earlier this month for research in microgravity, with the goal of furthering our understanding of neurogenerative diseases back on earth.
The models incorporate microglia, the inflammatory cells of the immune system that are implicated in the development of Parkinsons, multiple sclerosis, and other neurodegenerative diseases, explains Paula Grisanti, CEO of NSCF.
Studying the 3D models in microgravity, researchers are able to observe cell interaction, gene expression, and other developments not seen in a regular lab.
Its not possible for you to have this same 3D model of cell interaction on Earth. This will be the first time in space where we can see these in 3D, Grisanti tells Xconomy.
Cells behave differently in space, though its not completely understood why. Cartilage grows faster and bigger, proteins fold differently, and cells mature more rapidly. Being able to see this happen in real-timethe models will be filmed for the full 30 dayswill offer researchers unprecedented insight into neurodegenerative disease.
To see how those cells talk to each other for 30 days when they are up on the international space station will allow scientists to see the point at which things start to go awry in those diseases and hopefully identify a new place or a new point at which you could intervene with a cell or gene therapy that may or may not currently exist, says Grisanti.
The research will touch back down to earth in early January at which time both labs will analyze the models to determine what exactly happened during their time in space. All data will be published for full dissemination.
(Paul Kuehl, Jason Rexroat, Gentry Barnett, Valentina Fossati, Jason Stein, Scott Noggle, Jana Stoudemire. Image courtesy of Space Tango)
NSCF has budgeted for a year of post-flight research after which the researchers will send the models back to the space station for a second flight to confirm what they saw and test new hypotheses, explains Grisanti. A second year of post-flight research also is funded, as is a second flight at the end of 2020.
We know were going to see something new because it has never been done before, says Grisanti, who explains that the budget and project will continue to be extended as long as new theories and opportunities are being developed.
The December flight was the second for the research teams at Apsen and NYSCF. A preliminary flight was conducted in July 2019 to test the hardware systems and prepare for the SpaceX CRS-19 launch.
Aspen has also been pressing ahead with its own research on solid ground. Last week, the company closed a $6.5 million seed round led by Domain Associates and Axon Ventures.
Aspens cell therapy approach was developed by its co-founders, Jeanne Loring, professor emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute and Andres Bratt-Leal, a former post-doctoral researcher in Lorings lab. Also serving as Aspens chief scientific officer, Jeanne Loring was in May named Xconomys Stem Cell Pioneer of the Year.
(Main image: Experiment loaded for launch at Kennedy Space Center. Courtesy of Space Tango)
Melissa Fassbender is an Xconomy editor based in Chicago. You can reach her at email@example.com.
- MS in Stem Cell Biology and Regenerative Medicine - January 17th, 2022
- Home | Eli and Edythe Broad Center of Regeneration ... - January 17th, 2022
- Rising Focus on Exploring Potential of Stem Cells as Therapeutic Tools in Drug Targeting and Regenerative Medicine to Fuel Revenue Growth of Stem... - January 17th, 2022
- Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive - January 17th, 2022
- Companies In The Regenerative Medicine For Cartilage Market Increase R&D On Gene Therapy Technique As Per - Benzinga - January 17th, 2022
- Regenerative Medicine: The Promise Of Undoing The Ravages Of Time - Hackaday - January 17th, 2022
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 22nd, 2021
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2021-2028 - Increasing Demand for Body Reconstruction Procedures and Tissue Engineering -... - November 22nd, 2021
- Researchers use model of hypothalamus to implicate genes associated with sleep, BMI, puberty, and more - EurekAlert - November 22nd, 2021
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 28th, 2021
- Albert Einstein Cancer Center researcher receives NCI Outstanding Investigator Award to study two deadly blood diseases - EurekAlert - October 28th, 2021
- San Diego research centers receive $15 million to train next generation of scientists - Three San Diego research institutions have been awarded nearly... - October 28th, 2021
- Medical Innovation In Pet Healthcare Is Taking Things Up a Notch - Entrepreneur - October 28th, 2021
- UC Davis Medical Center faculty respond to the rise of treatments like Merck's anti-COVID pill - The Aggie - The Aggie - October 28th, 2021
- Managing superficial pyoderma with light therapy - DVM 360 - October 28th, 2021
- Completion of Enrollment in Phase III Comparative Study for Investigational Regenerative Cellular Medicine (gMSC1) for Knee Chondrogenesis Using... - October 28th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial - KMVT - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WIBW - October 5th, 2021
- Diabetic patient receives stem cell therapy - The Hindu - August 18th, 2021
- COVID- 19 Third Dose Approved for Certain Immunocompromised Individuals - the City of Cambridge - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- 3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along... - August 18th, 2021
- Some Residents Should Consider Third COVID-19 Vaccine Dose - Wyoming Department of Health - August 18th, 2021
- Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 - The Market Writeuo - The Market Writeuo - August 18th, 2021
- Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL - Targeted Oncology - August 18th, 2021
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily - August 5th, 2021
- Asia-Pacific Cell Therapy Market8 - Opportunities in the Approval of Kymriah and Yescarta - Markets Insider - August 5th, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - August 5th, 2021
- Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy |... - August 5th, 2021
- Gliomagenesis is orchestrated by the Oct3/4 regulatory network. - Physician's Weekly - August 5th, 2021
- Improving the Treatment Gap in Diffuse Large B-Cell Lymphoma - Targeted Oncology - August 5th, 2021
- Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress - StreetInsider.com - August 5th, 2021
- MUHS, Nashik to conduct fellowship course in regenerative medicine - BSI bureau - August 5th, 2021
- FDA Hands Out Surprising Rejection of Meduxus and Medac's Treosulfan - BioSpace - August 5th, 2021
- Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL - OncLive - August 5th, 2021
- Future Directions in the Treatment of Polycythemia Vera - OncLive - August 5th, 2021
- FDA Grants Priority Review to Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer - Business Wire - August 5th, 2021
- Cellino Appoints Industry Pioneer Robert J. Palay to the Board - Business Wire - August 5th, 2021
- Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF- Superfamily Member for the Treatment of Cancer - Yahoo Finance - August 5th, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 22nd, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 22nd, 2021
- John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large... - July 22nd, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 22nd, 2021
- Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan - Yahoo Eurosport UK - July 22nd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 22nd, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 22nd, 2021
- ViaCyte Appoints Dr. Jon Wilensky as Head of Surgery - PRNewswire - July 22nd, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 22nd, 2021
- Beyond CAR-T: New Frontiers in Living Cell Therapies - UCSF News Services - July 7th, 2021
- Sleeper cells, cells of origin and hematopoietic stem cells - Brain Tumour Research - July 7th, 2021
- Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML - PRNewswire - July 7th, 2021
- Researchers investigate whether stem cell therapy is safe and effective for treatment-resistant bipolar disease - Newswise - April 18th, 2021
- Stem Cell and Regenerative Therapy Market: Cell Therapy Segment to Dominate Global Market - BioSpace - April 18th, 2021
- First in the nation, FDA-approved Phase II mesenchymal stem cell therapy for Parkinson's disease begins - Newswise - April 18th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 18th, 2021
- Stem cell treatment needed to fight the good fight - Victoria Lookout - April 18th, 2021
- Being bionic: the future of regenerative medicine - Toronto Star - April 18th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 18th, 2021
- Chemical conversion of human epidermal stem cells into intestinal goblet cells for modeling mucus-microbe interaction and therapy - Science Advances - April 18th, 2021
- Andres Isaias Combining Innovation and Excellence - Influencive - April 18th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 18th, 2021
- Antibiotic Use Prior to Allogeneic Stem Cell Transplantation May Be Linked to Graft Vs Host Disease - Hematology Advisor - April 18th, 2021
- Mucopolysaccharidosis (MPS) Treatment Market Is Rising With Post COVID-19 Impact Analysis, Development, CAGR - Global Banking And Finance Review - April 18th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 18th, 2021
- The Governments Watchful Eye on Fraud Stemming from Stem Cell Therapy - JD Supra - April 4th, 2021
- Uprooting Cancer: Innovative Hydrogel Rapidly Reverts Cancer Cells Back to Cancer Stem Cells - SciTechDaily - April 4th, 2021
- Multiple sclerosis: Recent research on causes and treatments - Medical News Today - April 4th, 2021
- First CAR T-Cell Therapy for Multiple Myeloma: Abecma - Medscape - April 4th, 2021
- Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director - Benzinga - April 4th, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 4th, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 4th, 2021
- Russell Health Highlighted in the Silicon Review's '50 Leading Companies of the Year 2021' - PRNewswire - April 4th, 2021
- Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy... - April 4th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 4th, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 4th, 2021
- RenovaCare Announces Organizational Changes and Appointment of New Officers - GlobeNewswire - April 4th, 2021
- Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - March 8th, 2021
- Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine... - March 8th, 2021